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In addition to a line-up of topical articles, we are de-
lighted that our newest section, Drug Development in
Contemporary Oncology, under the editorship of Michel
Tremblay (Goodman Cancer Centre of McGill Uni-
versity), makes its debut in this issue of Current On-
cology. The first of a forthcoming series of
mini-reviews covers the histone deacetylase inhibitors.
Donald Walkinshaw and Xiang-Jiao Yang from the
Goodman Cancer Centre of McGill University present
a superb overview of the basic and clinical aspects of
this exciting new class of compounds for the treatment
of cancer.
In the section Oncologic History, Donald Cowan
(Cancer Care Ontario and Sunnybrook Health Sciences
Centre) provides an account of the invaluable pioneer-
ing contributions by Vera Peters to the diagnostic stag-
ing and treatment of Hodgkin disease. In the course
thereof, Dr. Cowan further provides the historical back-
drop to Peters’s work, featuring some of the other
prominent researchers who contributed to improve-
ments in the treatment of Hodgkin disease. Ironically,
Dr. Peters died of metastatic cancer in Princess
Margaret Hospital, where she served for many years.
Bone metastasis, the third most frequent compli-
cation of cancer (closely trailing liver and lung metas-
tasis), but oftentimes first as related to the primary
cancer, is the subject of two articles in this issue. In a
comparative analysis (with literature review) of pa-
tients receiving palliative radiotherapy for bone me-
tastasis, Amanda Hird and colleagues (Odette Cancer
Centre) observed similar rates of symptomatic pain
relief in patients with gastrointestinal (GI) primary can-
cer as in those with metastasis from other primary
cancer sites. Based on their observations, Hird et al.
emphasize that “patients with symptomatic bone
metastases from GI malignancies should be referred for
palliative radiotherapy as readily as patients with os-
seous metastases from other primary cancer sites.” In
the second report, Stephanie Hadi and colleagues (also
of the Odette Cancer Centre) aimed to validate “symp-
tom clusters” (SCs) among the factors interfering with
physical and psychological functions in patients receiving
palliative radiotherapy for their symptomatic bone pain.
These authors found that the SCs seen in recent pa-
tients were not the same as those seen in a previous
study group. Before making any final conclusions on
the usefulness of SCs, the authors suggest that evalua-
tion in a larger patient cohort is necessary.
Alan Nyitray (University of Arizona College of
Public Health) contributes to the Updates and Devel-
opments in Oncology section with a brief but concise
overview of human papillomavirus (HPV) in hetero-
sexual men. Vaccination for HPV will be the subject of
an upcoming supplement to the journal.
Wilson Cheung et al. (University of Toronto and
Odette Cancer Centre) bring us a unique caveat with
regard to ammonia levels in neuropsychiatric compli-
cations of 5-fluorouracil (5-FU) therapy for colon can-
cer. Their case report is additionally unique in describing
the first patient to develop 5-FU encephalopathy as a
result of FOLFOX chemotherapy, which has recently
become the new standard of care in therapy for
colorectal cancer.
Patients with chronic lymphocytic leukemia (CLL)
are at increased risk for secondary malignancies, for
which the mortality rate is high. Among these second-
ary malignancies, squamous cell carcinoma (SCC) is
particularly problematic. In a report of four cases of
SCC secondary to CLL, Jennifer Wong and colleagues
(Odette Cancer Centre) present findings of a favour-
able indication for radiotherapy after local recurrence
following surgical excision.
Our recently instituted method of publishing in a
combination of hard copy and electronic means has
permitted us to bring you three additional interesting
articles in this issue. To begin, a second report by
Jennifer Wong and colleagues (Odette Cancer Cen-
tre) provides a comprehensive literature review of
quality of life (QOL) results from trials of whole-brain
radiotherapy used alone and in combination with other
treatments for brain metastasis. The authors empha-
size the importance of including QOL as an endpoint
in future trials, so that a better understanding can be
obtained concerning the role of QOL, particularly for
improving treatment of patients with brain metasta-
sis. In a second online article, Max Dahele andABLIN
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colleagues (Princess Margaret Hospital, University
of Toronto, and Sunnybrook Health Sciences Centre)
meticulously report, using color images, their initial
experience with an innovative approach for three-di-
mensional correlation of positron-emission and com-
puted tomography images with whole-mount
histopathology in non-small-cell lung cancer. Their
methodologic principles may be readily transferable
to other tumour types. Finally, Flynn et al. (Sunnybrook
Health Sciences Centre) present two cases of
acrometastasis to the hands, and an extensive review
of the literature. With lung cancer being the number
one primary cancer site metastasizing to the hands
(followed by kidney and breast cancers), the well-
documented report by these authors confirms that a
diagnosis of hand metastasis indicates poor progno-
sis, average survival being 6 months.
We at Current Oncology continue to strive to bring
you timely and topical articles. However, we need to
hear your comments on whether we are succeeding in
that endeavour and your suggestions of specific topics
that you would like to see covered in the journal. We
welcome your comments, which should be sent to
Laura Shand at current_oncology@multi-med.com.